Clinical trials: Inflammatory Disorder
Ulcerative Colitis
(CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis
This will be a multicentre, randomised, double-blind, double-dummy, parallel group comparative study in patients with mild or moderate, active ulcerative colitis.
- Trial name
- NCT00679380
- Testing
- Blood sampling, endoscopy, Budesonide MMX® 6 mg, Budesonide MMX® 9 mg
- Where
- 71 sites in Australia, Belgium and 13 more
- Volunteers
- 514 people
- Sponsor
- Bausch Health Americas, Inc.
Preterm Birth
Study of Cervix and Inflammation in Preterm Birth Prediction
Preterm birth rate is 7.2% in Quebec, it's risen worldwide in the past decade and it's the leading cause of perinatal mortality and morbidity. Preterm birth is a major public health problem.
- Trial name
- COLIBRI (NCT01007513)
- Testing
- Transvaginal ultrasound, Vaginal secretion sampling
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Université de Sherbrooke
Stable Angina, Heart Failure
Association Between Inflammatory Biomarkers in CVD Patients on Empagliflozin.
The association of novel inflammatory biomarkers with cardiovascular diseases is still obscure. The present study aimed to investigate the relationship of various inflammatory biomarkers with the existence as well as the extent…
- Trial name
- NCT05911724
- Testing
- Group I Healthy, CAD-Empagliflozin 10 mg once daily for 6 months before the beginning of the study, HF-Empagliflozin 10 mg once daily for 6 months before the beginning of the study
- Where
- Egypt
- Volunteers
- 180 people
- Sponsor
- Damanhour University
Inflammatory Bowel Diseases, Crohn Disease
The PRognostic Effect of Environmental Factors in Crohn's and Colitis
The PREdiCCt Study: This is a major study that is now being launched. This is the first study of its kind and is specifically directed toward understanding how environmental factors and the gut microorganisms influence IBD flare…
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
- Trial name
- PREdiCCt (NCT03282903)
- Where
- 41 sites in United Kingdom
- Volunteers
- 2,629 people
- Sponsor
- University of Edinburgh
Mb Crohn, Ulcerative Colitis (UC)
Uneven Nutrition and Life Style as IBD Triggers in Adolescents and Adults
The aims of the study are 1. to determine the effect on dysbiosis, permeability and inflammatory activity after administration of a Mediterranean like diet (a Nordic equivalent, "Nordiet"), 2.
- Trial name
- UNITA (NCT07389161)
- Testing
- Nordiet
- Where
- Sweden
- Volunteers
- 160 people
- Sponsor
- Region Skane
Crohn's Disease
Cimzia Versus Mesalamine for Crohn's Recurrence
Hypothesis: Cimzia provides superior reduction in endoscopic and clinical recurrence rates compared to mesalamine in the treatment of Crohn's disease one-year following ileocolectomy for Crohn's disease. 1.
- Trial name
- NCT01696942
- Testing
- Cimzia, Mesalamine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Milton S. Hershey Medical Center
Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Frailty
Immune Aging and Advanced Therapy Outcomes in Older Adults With IBD
The goal of this observational study is to learn whether signs of immune aging and frailty can help predict the balance of benefits and risks of advanced therapies in adults aged 60 years or older with inflammatory bowel disease…
- Conditions
- Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Frailty, Immunosenescence
- Trial name
- NCT07828886
- Volunteers
- 300 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Psychotic Disorders
Hormonal and Inflammatory Biomarkers and Response to Cognitive Remediation in Recent-onset Psychosis
This study aims to explore whether hormones or inflammatory markers are associated with cognitive changes following cognitive remediation therapy (CRT) in people with a recent-onset psychotic disorder.
- Trial name
- NCT04418570
- Testing
- cognitive remediation, attendance to an Early Intervention Service for Psychosis
- Volunteers
- 28 people
- Sponsor
- Corporacion Parc Tauli
Asthma
Anti-Inflammatory Lipid Mediators in Asthma
The purpose of this study is to demonstrate the efficacy and safety of 10-nitro-9(E)-octadec-9-enoic acid (CXA-10) in obese adult asthmatics.
- Trial name
- ALMA (NCT03680976)
- Testing
- CXA-10
- Where
- United States
- Sponsor
- Sally E. Wenzel MD
Septic Shock, Ascorbic Acid Deficiency
Outcomes of Septic Shock Patients Treated With a Metabolic Resuscitation Bundle Consisting of Intravenous Hydrocortisone, Ascorbic Acid and Thiamine.
This is a retrospective chart review that will measure the impact on outcomes in septic shock patients who were resuscitated with a novel combination of medicines called iHAT (intravenous hydrocortisone -ascorbic acid-thiamine).
- Trial name
- NCT03913468
- Testing
- Intravenous Ascorbic Acid
- Where
- United States
- Volunteers
- 206 people
- Sponsor
- University of Wisconsin, Madison
Heart Valve Diseases, Systemic Inflammatory Response Syndrome
Corticosteroid Prophylaxis on the Cardiopulmonary Bypass-Induced Systemic Inflammatory Response
To observe the effect of glucocorticoid on the dynamic changes of monocyte subsets in the peripheral blood of valve disease patients undergoing cardiopulmonary bypass perioperatively.
- Trial name
- NCT01296074
- Testing
- Corticosteroid
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Anzhen Hospital
Ulcerative Colitis (UC)
Palmitoylethanolamide in Ulcerative Colitis
Evaluate the effects of PEA supplementation on disease activity, health-related quality of life (HRQoL) and inflammatory biomarkers in patients with active mild-to-moderate UC.
- Trial name
- NCT07609810
- Testing
- Palmitoylethanolamide (PEA)
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
SLE (Systemic Lupus), Systemic Sclerosis
Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
This is an open clinical pharmacological translational Research Study, aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of CD19 or CD19-BCMA CAR-T in patients with active SLE, SSc, AAV…
- Conditions
- SLE (Systemic Lupus), Systemic Sclerosis, ANCA Associated Vasculitis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT06548607
- Testing
- CD19 or CD19-BCMA CAR-T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Nanjing Bioheng Biotech Co., Ltd.
Coronary Heart Disease, Dyslipidemia
The Hellenic Postprandial Lipemia Study (HPLS)
Coronary heart disease (CHD) is the leading cause of death worldwide. The disease is characterized by a high mortality rate (about 40%) and a course continuously altered by lifestyle, gene polymorphisms and therapeutic treatment.
- Trial name
- HPLS (NCT02163044)
- Where
- Greece
- Volunteers
- 580 people
- Sponsor
- Hellenic College of Treatment of Atherosclerosis
Colorectal Cancer
Changes in Stem Cells of the Colon in Response to Increased Risk of Colorectal Cancer
Colorectal cancer is a common disease worldwide. Increasing evidence is demonstrating that colorectal cancers arise from 'cancer stem cells.' Stem cells in the colon reside at the bottom of thousands of microscopic crypts…
- Trial name
- NCT01075893
- Where
- 2 sites in United Kingdom
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Newcastle University
Vogt Koyanagi Harada Disease, Serpiginous Choroiditis
Intravitreal Bevacizumab for Inflammatory Neovascular Membranes
Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to intraocular inflammation. We injected a single injection of Bevacizumab (2.5 mg/0.1 ml) and evaluate visual acuity , Fluorescein angiogram…
- Conditions
- Vogt Koyanagi Harada Disease, Serpiginous Choroiditis, Multifocal Choroiditis
- Trial name
- NCT00407121
- Testing
- Bevacizumab, Intravitreal Injection of Bevacizumab
- Where
- Mexico
- Sponsor
- Asociación para Evitar la Ceguera en México
HER2-positive Breast Cancer, Recurrent Breast Cancer
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
This phase II trial studies how well pertuzumab, trastuzumab, and paclitaxel albumin-stabilized nanoparticle formulation work in treating patients with human epidermal growth factor receptor (HER) 2-positive stage II-IV breast…
- Conditions
- HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
- Trial name
- NCT01730833
- Testing
- pertuzumab, trastuzumab, paclitaxel albumin-stabilized nanoparticle formulation
- Where
- 3 sites in United States
- Volunteers
- 63 people
- Sponsor
- City of Hope Medical Center
Inflammatory Bowel Disease (IBD)
Efficacy Safety Study of Flu Vaccine in Immunodepression Patients
The primary purpose of the study is to compare the efficacy and safety of influenza vaccine in patients with inflammatory bowel disease (IBD) receiving immunosuppressive therapy with patients not receiving immunosuppressants .
- Trial name
- MICIVAX (NCT01022749)
- Testing
- Vaccine, Vaccine anti-H1N1
- Where
- France
- Volunteers
- 228 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
CKD (Chronic Kidney Disease) Stage 5D, Uremia; Chronic
Studies on Adsorption International Learning Initiative Global
Use of sorption technologies in patients undergoing maintenance hemodialysis with inflammatory syndrome and clinical manifestations of uremia
- Conditions
- CKD (Chronic Kidney Disease) Stage 5D, Uremia; Chronic, Uremic; Toxemia, Inflammation Chronic
- Trial name
- SAILING (NCT07123909)
- Testing
- Patients will undergo a combined hemodialysis and hemosorption procedure. The study cartridge for hemosorption by Jafron HA130 contains the original adsorbing material.
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- Botkin Hospital
Ulcerative Colitis
Infliximab Accelerated Induction in Moderate to Severe Pediatric UC
Objectives: To examine the effect of accelerated infliximab induction in children with moderate to severe UC. Design: A multi-center, prospective, randomized, open label study. Setting: Pediatric gastroenterology centers.
- Trial name
- INDUCE (NCT03209232)
- Testing
- Infliximab
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Schneider Children's Medical Center, Israel
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.